SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of the International Association of Physicians in AIDS Care (JIAPAC)
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1545109707304494v1
6/3/206    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kim, A. A.
Right arrow Articles by Weidle, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, A. A.
Right arrow Articles by Weidle, P. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Adverse Events in HIV-Infected Persons Receiving Antiretroviral Drug Regimens in a Large Urban Slum in Nairobi, Kenya, 2003-2005

Andrea A. Kim

Global AIDS Program, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA, aakim{at}cdc.gov

Lucy Wanjiku

Global AIDS Program, CDC-Kenya, Nairobi, Kenya

Doris K. Macharia

Global AIDS Program, CDC-Kenya, Nairobi, Kenya

Mary Wangai

Republic of Kenya Ministry of Health, Nairobi, Kenya

Anthony Isavwa

Global AIDS Program, CDC-Kenya, Nairobi, Kenya

Hussein Abdi

Global AIDS Program, CDC-Kenya, Nairobi, Kenya

Barbara J. Marston

Global AIDS Program, CDC-Kenya, Nairobi, Kenya

Festus Ilako

African Medical Research Foundation-Kenya, Nairobi, Kenya

Mette Kjaer

African Medical Research Foundation-Kenya, Nairobi, Kenya

Kenneth Chebet

Republic of Kenya Ministry of Health, Nairobi, Kenya

Kevin M. De Cock

Global AIDS Program, CDC-Kenya, Nairobi, Kenya

Paul J. Weidle

Division of HIV/AIDS Prevention, CDC, Atlanta, Georgia, USA

Objective: This article describes toxicities to antiretroviral therapy (ART) among HIV-infected patients receiving care at a clinic in a large urban slum in Nairobi, Kenya. Methods: Patients were treated with nonnucleoside reverse transcriptase inhibitor-based ART and followed at scheduled intervals. Frequencies and cumulative probabilities of toxicities were calculated. Results: Among 283 patients starting ART, any and severe clinical toxicity were recorded as 65% and 6%, respectively. Cumulative probabilities for remaining free of any and severe clinical toxicities at 6, 12, and 18 months, were 0.47, 0.26, and 0.17, respectively and 0.98, 0.95, and 0.89, respectively. The probability of remaining free from elevated and grade 3 or 4 serum aminotransferase (AST) at 6, 12, and 18 months were 0.62, 0.42, and 0.21, respectively, and 0.99 at 6, 12, and 18 months. Conclusions: ART toxicities were frequent, but severe toxicities were less common. In resource-limited settings, ART toxicity should not represent a barrier to care.

Key Words: HIV • antiretroviral therapy • nonnucleoside reverse transcriptase inhibitor • toxicity • Africa

This version was published on September 1, 2007

Journal of the International Association of Physicians in AIDS Care (JIAPAC), Vol. 6, No. 3, 206-209 (2007)
DOI: 10.1177/1545109707304494
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement